论文部分内容阅读
31例血清甲胎蛋白(αFP)阳性(其中15例αFP异质体阳性,24例α-DNA结合蛋白(α-DBP)阳性,影像学检查未见肝脏有占位病变)的肝癌前期(高危)患者分成甲乙两组。甲组(用被CD_3单克隆抗体激活的杀伤细胞CD_3AK,加α-干扰能治疗)20人,乙组(用α-干扰能加胸腺肽治疗)11人。结果:αFP、αFP异质体和α-DBP转为正常的机率在甲组分别为95％、75％、50％;在乙组分别为29.7％、28.9％、9％。两组间差异显著(P<0.05)。提示CD_3细胞加α-干扰能对肝癌前期病变的疗法确属可行。
31 cases of alpha-fetoprotein (alpha FP) were positive (15 of them were heterozygous for αFP, 24 were positive for α-DNA-binding protein (α-DBP), and imaging did not show lesions in the liver). Patients were divided into two groups. Group A (killed with CD_3 monoclonal antibody-activated killer CD_3AK, plus alpha-interferon therapy) was 20, and Group B (treated with alpha-interfering plus thymosin) was 11. RESULTS: The odds of αFP, αFP heterogeneity, and α-DBP turning normal were 95%, 75%, and 50% in group A, and 29.7%, 28.9%, and 9% in group B, respectively. There was a significant difference between the two groups (P<0.05). It is suggested that the treatment of precancerous lesions of hepatocellular carcinoma by CD_3 cells plus α-interfering energy is indeed feasible.